HC Wainwright & Co. Reiterates Buy on Verrica Pharmaceuticals, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained an $11 price target.
July 17, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Verrica Pharmaceuticals (NASDAQ:VRCA) has had its 'Buy' rating reiterated and $11 price target maintained by HC Wainwright & Co.
The reiteration of a 'Buy' rating and maintenance of the $11 price target by HC Wainwright & Co. indicates a positive outlook for Verrica Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100